Search

Your search keyword '"Joe Sasadeusz"' showing total 5 results
Start Over Author "Joe Sasadeusz" Publisher elsevier
5 results on '"Joe Sasadeusz"'

1. Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapyResearch in context

Author

Kasha P. Singh, Anchalee Avihingsanon, Jennifer M. Zerbato, Wei Zhao, Sabine Braat, Surekha Tennakoon, Ajantha Rhodes, Gail V. Matthews, Christopher K. Fairley, Joe Sasadeusz, Megan Crane, Jennifer Audsley, and Sharon R. Lewin

Subjects
HIV, Hepatitis, Liver, Fibrosis, HMGB1, Medicine, Medicine (General), R5-920
Abstract

Summary: Background: In people living with HIV-HBV, liver fibrosis progression can occur even with suppressive antiretroviral therapy (ART). We investigated the relationship between liver fibrosis and biomarkers of inflammation, apoptosis, and microbial translocation. Methods: In this observational cohort study adults living with HIV-HBV already on effective ART were recruited in Australia and Thailand and followed for 3 years including 6 monthly clinical review and blood tests and annual transient elastography. Differences in clinical and laboratory predictors of liver fibrosis progression were tested followed by regression analysis adjusted for CD4+ T-cells at study entry. A linear mixed model was fitted to longitudinal data to explore changes over time. Findings: 67 participants (85% male, median age 49 y) were followed for 175 person-years. Median duration of ART was 10 years (interquartile range (IQR) 8–16 years). We found 11/59 (19%) participants during 3-years follow-up (6/100 person-years) met the primary endpoint of liver disease progression, defined as increased Metavir stage from baseline to final scan. In regression analysis, progressors compared to non-progressors had higher levels of high mobility group box 1 protein (HGMB1), (median (IQR) 3.7 (2.6–5.0) and 2.4 ng/mL (1.5–3.4) respectively, adjusted relative risk 1.47, 95% CI [1.00, 2.17]) and lower nadir CD4+ T-cell percentage (median 4% (IQR 2–8) and 11% (4–15) respectively (relative risk 0.93, 95% CI [0.88, 0.98]). Interpretation: Progression in liver fibrosis occurs in people with HIV-HBV on suppressive ART. Fibrosis progression was associated with higher HMGB1 and lower percentage nadir CD4+ T-cell count, highlighting the importance of early initiation of HBV-active ART. Funding: This work was supported by NHMRC project grant 1101836; NHMRC practitioner fellowship 1138581 and NHMRC program grant 1149990. The funder had no role in study design, data collection, data analysis, interpretation, writing of this manuscript or decision to submit for publication.

Published
2024
Full Text
View/download PDF

2. Cat-Scratch Disease Masquerading as C3 Glomerulonephritis

Author

Joe Sasadeusz, Moira Finlay, Shio Yen Tio, Lucy C Fox, Benjamin Sutu, Thomas D. Barbour, and Piers Blombery

Subjects
medicine.medical_specialty, Nephrology, business.industry, C3 Glomerulonephritis, MEDLINE, Medicine, Cat-scratch disease, business, medicine.disease, Nephrology Rounds, Dermatology
Published
2020

3. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Author

Gail V. Matthews, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya L. Applegate, Jason Grebely, Phillipa Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, Marc van der Valk, Greg Dore, Pip Marks, Gail Matthews, Tanya Applegate, Jordan Feld, Jürgen Rockstroh, Sophia Amjad, Elise Tu, Mahshid Tamaddoni, Maria Christine Thurnheer, Yvonne Gilleece, Chris Fraser, Alberto Moriggia, Thomas Lutz, Juhi Moon, Phillip Read, Arthur Y. Kim, Andrew Ustianowski, Christiane Cordes, Joe Sasadeusz, Mark Hull, Dominique Braun, Infectious diseases, AII - Infectious diseases, APH - Digital Health, APH - Personalized Medicine, and APH - Global Health

Subjects
0301 basic medicine, Male, Time Factors, Sofosbuvir, Human immunodeficiency virus (HIV), recently acquired, medicine.disease_cause, Virological response, 0302 clinical medicine, Germany, Clinical endpoint, Short course, 610 Medicine & health, Netherlands, education.field_of_study, treatment, short duration, acute, Hepatitis C, Middle Aged, Drug Combinations, Treatment Outcome, HCV, 030211 gastroenterology & hepatology, Female, Switzerland, medicine.drug, Adult, medicine.medical_specialty, Canada, Population, Sofosbuvir/velpatasvir, Antiviral Agents, Heterocyclic Compounds, 4 or More Rings, Article, 03 medical and health sciences, Internal medicine, medicine, Humans, education, direct-acting antivirals, Hepatology, business.industry, Australia, medicine.disease, United Kingdom, 030104 developmental biology, Carbamates, business, New Zealand
Abstract

Background & Aims Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking. Methods REACT was an NIH-funded multicentre international, open-label, randomised, phase IV non-inferiority trial examining the efficacy of short course (6-week) vs. standard course (12-week) therapy with sofosbuvir-velpatasvir for recent HCV infection (estimated duration of infection ≤12 months). Randomisation occurred at week 6. The primary endpoint was sustained virological response 12 weeks after treatment end (SVR12) in the intention-to treat (ITT) population. A total of 250 participants were due to be enrolled, but on advice of the data safety and monitoring board the study was halted early. Results The primary analysis population consisted of 188 randomised participants at termination of study enrolment; short arm (n = 93), standard arm (n = 95). Ninety-seven percent were male and 69% HIV positive. ITT SVR12 was 76/93, 81.7% (95% CI 72.4–89.0) in the short arm and 86/95, 90.5% (95% CI 82.7–95.6) in the standard arm. The difference between the arms was -8.8 (95% CI -18.6 to 1.0). In modified ITT analysis, wherein non-virological reasons for failure were excluded (death, reinfection, loss to follow-up), SVR12 was 76/85, 89.4% (95% CI 80.8–95.0) in the short arm and 86/88, 97.7% in the standard arm (95% CI 92.0–99.7; difference -8.3%, p = 0.025). Conclusions In this randomised study in recent HCV infection, a 6-week course of sofosbuvir-velpatasvir did not meet the criteria for non-inferiority to standard 12-week therapy. Lay summary In this randomised trial, 188 people with recently acquired hepatitis C infection were randomly assigned to treatment using either a short 6-week course (93 people) or standard 12-week course (95 people) of the hepatitis C treatment sofosbuvir/velpatasvir. There were 9 cases of relapse after treatment with the short course and 2 following the standard course. A shortened course of 6-week therapy for hepatitis C infection appeared to be less effective than a standard 12-week course in people with recently acquired hepatitis C infection. ClinicalTrials.gov Identifier NCT02625909 .

Published
2021

4. O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective

Author

A.L. Bowring, B.K. Tee, Mark O’Reilly, Janine Roney, J. Cutts, Margaret Hellard, Jennifer F Hoy, Christopher K. Fairley, E.J. Gane, Robert B. Moore, Gail V. Matthews, Joseph Doyle, Mark Stoove, Maria Prins, Joe Sasadeusz, Nicholas A. Medland, and David Iser

Subjects
Epidemiology, business.industry, Immunology, Public Health, Environmental and Occupational Health, Primary care, Hepatitis C, medicine.disease, Virology, Microbiology, QR1-502, Infectious Diseases, Hcv treatment, Medicine, Public aspects of medicine, RA1-1270, business, Co infection
Published
2017

5. O14 Community prescribing of hepatitis C treatment: a mentorship and capacity building model to increase treatment uptake by targeted populations

Author

G. Bartlett, L. Accadia, T. Schulz, T. Shanahan, Joe Sasadeusz, L. Coelli, and S. Watkinson

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Immunology, Public Health, Environmental and Occupational Health, Capacity building, Hepatitis C, medicine.disease, Microbiology, QR1-502, Infectious Diseases, Mentorship, Virology, Family medicine, medicine, Public aspects of medicine, RA1-1270, business
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results